- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.08. | FDA accepts Exelixis' cabozantinib sNDA for neuroendocrine tumours | ||
| 06.08. | Santen and Cloudbreak enter licence agreement for pterygium treatment | ||
| 05.08. | Genmab assumes full ownership of acasunlimab | ||
| 02.08. | Health Canada grants approval for Celltrion's Steqeyma for multiple conditions | ||
| 01.08. | Jade Biosciences secures $80m to develop autoimmune therapies | ||
| 31.07. | Pinetree secures $17m to advance TPD development programmes | ||
| 30.07. | FDA approves Alpha Cognition's ZUNVEYL for Alzheimer's treatment | ||
| 29.07. | LEO Pharma obtains positive EMA CHMP opinion for eczema treatment | ||
| 26.07. | Confo Therapeutics secures €60m funds to progress GPCR-modulating therapies | ||
| 25.07. | Oisín secures funds to advance treatments for age-related ailments | ||
| 24.07. | FDA grants RMAT designation to AffyImmune's AIC100 for thyroid cancer | ||
| 23.07. | Vividion Therapeutics to expand capabilities with new R&D centre in US | ||
| 22.07. | Apollo Therapeutics and University of Oxford sign drug discovery partnership | ||
| 19.07. | Diamyd Medical secures FDA fast track status for type 1 diabetes treatment | ||
| 18.07. | Lynch Regenerative Medicine secures funds to develop skin regeneration solutions | ||
| 17.07. | Merck KGaA launches GMP-compliant cell culture media line in China | ||
| 16.07. | US FDA grants RMAT designation for Kyverna's KYV-101 | ||
| 15.07. | Merck enhances ophthalmology portfolio with EyeBio acquisition | ||
| 12.07. | Leqembi gains approval for Alzheimer's treatment in Israel | ||
| 11.07. | Cosette Pharmaceuticals acquires Ambien rights in US | ||
| 10.07. | Amneal Pharmaceuticals launches ready-to-use injectable FOCINVEZ | ||
| 09.07. | Adicet Bio's ADI-270 receives FDA Fast Track Designation for kidney cancer treatment | ||
| 08.07. | EU approves AstraZeneca's Tagrisso combined with chemotherapy for EGFRm NSCLC | ||
| 05.07. | Alembic receives tentative approval from USFDA for Ivosidenib Tablets | ||
| 04.07. | Beacon Therapeutics secures $170m to expedite gene therapy development |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
